Clinical trials
Thyroid Cancer clinical trials
Below are recruiting thyroid cancer clinical trials, each written for real people, not researchers. We’re tracking 171 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07092514RecruitingPhase 2
Comparing two doses of lenvatinib for thyroid cancer not helped by iodine
This study compares two doses of lenvatinib (24 mg vs 10 mg per day) to see which works better for people with thyroid cancer that no longer responds to radioactive iodine. It's for those whose cancer is growing or causing symptoms.
St Louis, MissouriAges 18 years+ - NCT06254859Recruiting
Nerve monitoring during thyroid surgery and voice outcomes
This study tests whether using nerve monitoring during thyroid surgery helps protect the nerves that control your voice. It includes adults having one side of their thyroid removed and tracks voice changes before and after surgery.
Fuzhou, FujianAges Any age - NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06980103Recruiting
Decision aid for RAI in thyroid cancer
This trial offers a decision aid to help you choose whether to have radioactive iodine (RAI) treatment after thyroid cancer surgery. You may qualify if you have intermediate-risk thyroid cancer and haven't yet made a decision about RAI.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06961084RecruitingPhase 2
I-124 PET/CT scan for diagnosing thyroid cancer
This trial tests whether a new type of scan (I-124 PET/CT) can better detect thyroid cancer compared to standard scans. It may help doctors decide on the best treatment, such as radiation therapy or surgery.
San Francisco, CaliforniaAges 13 years+ - NCT06923826RecruitingPhase 2
Study of sacituzumab govitecan for advanced salivary gland and thyroid cancers
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
SingaporeAges 21 years+ - NCT06902376RecruitingPhase 1
XL092 and cemiplimab for advanced thyroid cancer without BRAF mutation
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
Boston, MassachusettsAges 18 years+ - NCT06851663RecruitingPhase 2/Phase 3
New PET scan for many solid tumors
This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.
ShanghaiAges 18–75 - NCT06796348Recruiting
Needle treatment vs surgery for small thyroid cancers
This study compares a non-surgical procedure (radiofrequency ablation) with partial thyroid removal (hemithyroidectomy) for treating small thyroid cancers. It aims to find out if the needle-based treatment is as effective as surgery, with fewer side effects.
AarhusAges 30 years+ - NCT06730321Recruiting
Assessing skills for robotic thyroid surgery
This trial is for people having robotic thyroid surgery (removing all or part of the thyroid with a robot). It aims to create a scoring system to measure how well surgeons perform the procedure. You may be eligible if you have a small thyroid cancer or a benign nodule and want the best cosmetic result.
ShanghaiAges Any age - NCT05752604Recruiting
Study of treatments and factors in thyroid cancer
This study looks at thyroid cancer and how standard treatments and other health details relate to outcomes. You might be eligible if you have thyroid cancer and can participate by giving informed consent.
MilanAges Any age - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06524167Recruiting
Radiation therapy after surgery for advanced thyroid cancer
This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.
ShanghaiAges 14–80 - NCT06458036RecruitingPhase 2
Selpercatinib before radioactive iodine for RET-positive thyroid cancer
This study tests whether a targeted drug called selpercatinib, taken before radioactive iodine therapy, can help treat thyroid cancer in children and young adults who have a specific genetic change (RET fusion or mutation). The drug may make the cancer more sensitive to the radioactive iodine treatment that follows.
San Francisco, CaliforniaAges 2–25 - NCT06261190Enrolling by invitation
Active monitoring for low-risk thyroid cancer
This trial tests whether it is safe to avoid immediate surgery and instead monitor small thyroid cancers that are considered low-risk. If you join, doctors will check regularly to make sure the cancer does not grow or spread.
Goyang-siAges 18 years+ - NCT06235216RecruitingPhase 2
Sacituzumab govitecan for advanced thyroid cancer
This trial tests a new drug called sacituzumab govitecan for people with advanced thyroid cancer that has stopped responding to standard treatments. It may be an option for those with differentiated thyroid cancer (after certain prior therapies) or anaplastic thyroid cancer (first-line or after one prior treatment).
BarcelonaAges 18 years+ - NCT05024929Recruiting
Test targeted drugs to help radioactive iodine reach thyroid cancer
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
San Francisco, CaliforniaAges birth+ - NCT05783323RecruitingPhase 2
Larotrectinib plus radiation for thyroid cancer with NTRK fusion
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
San Francisco, CaliforniaAges 2–99 - NCT05733013Recruiting
Using redifferentiation medicines before radioactive iodine for thyroid cancer
This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.
New York, New YorkAges 18 years+ - NCT05172921Recruiting
Study of environmental factors in thyroid cancer risk
This study looks at how environmental exposures may relate to thyroid cancer. If you have a suspicious thyroid nodule and are planning surgery, your biopsy or surgical tissue may be used to understand risk factors.
New York, New YorkAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99 - NCT04742608Recruiting
Liquid blood tests to diagnose thyroid nodules or cancer
This study tests whether a blood “liquid biopsy” can help diagnose thyroid cancer or hard-to-tell thyroid nodules without needing extra procedures. It may help confirm what’s going on before or around planned thyroid surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT03841617RecruitingPhase 2
Measure radiation in thyroid cancer using a special PET-CT scan
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
Bethesda, MarylandAges 18–90 - NCT03765333Recruiting
Registering people with thyroid cancer for a study
This study is a registry that collects information about adults with certain types of thyroid cancer. It may help researchers learn more about these cancers and how people are doing over time.
Barcelona, BarcelonaAges 18 years+
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thyroid cancer?
- Yes. Clin2 currently lists 171 recruiting thyroid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thyroid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thyroid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.